AZD1222 COVID-19 Vaccine Trial Comes to Downtown Phoenix, AZ at Bayless Integrated Healthcare

AZD1222 COVID-19 Vaccine Trial Comes to Downtown Phoenix, AZ at Bayless Integrated Healthcare

Bayless Integrated Healthcare, located in downtown Phoenix, Arizona, was selected by AstraZeneca for the Phase 3 clinical trial investigating the efficacy of AZD1222, the COVID-19 vaccine originally developed at University of Oxford.  Targeting 1, 500 participants, some of whom will come from the health provider’s pool of approximately 30,000 patients.  The actual study is being managed by CCT Research. The study team will monitor the participants for two years after the experimental inoculation. The study is offered in both English and Spanish.

The Vaccine

This is one of the leading vaccine candidates developed by Oxford University’s Jenner Institute, (ChAdOx1 nCoV-19). Made from a weakened version of a common cold virus (adenovirus), the candidate, which triggers infections in chimpanzees, was genetically modified so that it can’t grow in humans. The UK-based scientists added genetic material  used to make proteins from COVID-19 known as the Spike glycoprotein (S), typically located on the surface of the pathogen and that serves as an instrumental element associated with the infection of the virus. That’s because the pathogen uses its spike protein to bind to ACE2 receptor...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee